Researchers from the Vlaams Instituut voor Biotechnologie and KU Leuven have successfully identified the precise biological mechanism behind the widely used Alzheimer’s drug lecanemab. Published in Nature Neuroscience on March 17, 2026, the study reveals how the Fc fragment activates brain immune cells. This discovery resolves long-standing questions about the therapy's efficacy and safety profile for millions of patients worldwide. The findings mark a significant milestone in understanding monoclonal antibody treatments for neurodegenerative conditions. This breakthrough offers new clarity on why the drug slows cognitive decline in clinical settings.
Lecanemab, marketed as Leqembi, targets harmful amyloid plaques to slow cognitive decline in patients suffering from dementia. Researchers found that the antibody’s Fc fragment acts as a trigger for microglia to clear toxic deposits effectively. Without this specific component, the treatment loses its effectiveness in clearing plaques completely from the brain tissue. This distinction explains why some patients responded better than others in previous clinical trials. The mechanism highlights the critical role of immune system engagement in therapeutic success.
The team utilized a hybrid mouse model containing human microglial cells to observe the interaction closely under controlled conditions. Dr. Giulia Albertini, a co-first author, stated that the Fc fragment works as an anchor for microglia during the process. This reprogramming allows cells to remove amyloid plaques more efficiently than before without damaging surrounding neurons. Magdalena Zielonka noted that testing human-specific responses provided unprecedented resolution for the data. Their approach allowed for direct observation of antibody interactions with human immune cells.
More than 55 million people worldwide live with Alzheimer’s disease driven by toxic protein buildup in their neural networks. Previous antibody therapies faced limitations due to unclear modes of action and significant side effects that hindered adoption. This study provides the first clear explanation of how this specific class of therapy functions in humans at a cellular level. The data suggests that immune activation is the primary driver of therapeutic success in this context. Understanding this pathway is crucial for future drug development strategies.
Advanced techniques like single-cell and spatial transcriptomics identified specific gene activity patterns within the brain tissue. The researchers noted strong expression of the gene SPP1 during effective plaque removal processes in the model. These biological processes were only triggered when the Fc fragment remained intact and functional throughout the treatment cycle. The study utilized NOVA-ST to uncover these patterns with high precision. This methodological rigor ensures the reliability of the findings for the scientific community.
Prof. Bart De Strooper concluded that understanding the Fc fragment guides next-generation drug design significantly for the industry. Future treatments may activate microglia directly without relying on full antibodies for delivery to the target site. This could lead to safer and more effective options for patients globally who require better management strategies. The research team emphasized that safety improvements are a key priority for upcoming pharmaceutical developments. Industry leaders are already considering how to apply these insights to pipeline projects.
The research received support from the European Research Council and the Alzheimer’s Association USA during the project. Additional backing came from the Research Foundation Flanders and the UK Dementia Research Institute University College London. These partnerships highlight the international effort to combat neurodegenerative diseases effectively through shared resources. Funding from multiple regions ensures broad applicability of the findings to different healthcare systems. Collaboration across borders remains essential for solving complex medical challenges.
The findings open doors for therapies that bypass antibody requirements entirely in future development pipelines. Scientists will now focus on replicating the microglial program identified in the study results for clinical application. This shift could redefine the standard of care for dementia management in coming years across major healthcare systems. Industry analysts expect this breakthrough to influence investment strategies in the biotechnology sector. The global health community watches for the next phase of clinical trials.
